Stock AUTL AUTOLUS THERAPEUTICS PLC
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Autolus Therapeutics plc

Equities

AUTL

US05280R1005

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
3.8 USD -5.00% Intraday chart for Autolus Therapeutics plc -16.67% -40.99%
Apr. 25 European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Thursday Trading MT
Apr. 19 European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading But End Week Down MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO
GL
Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
GL
Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (B-ALL)
GL
Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (B-ALL)
AQ
Autolus Therapeutics Announces Changes to its Board of Directors
GL
Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates
GL
Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates
AQ
Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site
GL
Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site
AQ
Autolus Therapeutics announces publication in Blood Cancer Journal
GL
Autolus Therapeutics announces publication in Blood Cancer Journal
AQ
Autolus Therapeutics to Report Full Year 2023 Financial Results and Business Updates on March 14, 2024
GL
Autolus Therapeutics to Report Full Year 2023 Financial Results and Business Updates on March 14, 2024
AQ
Autolus Therapeutics announces publication in Nature Communications 
GL
Autolus Therapeutics announces publication in Nature Communications 
AQ
BioNTech agrees collaboration to accelerate autologous CAR-T therapies
AQ
Autolus Announces Pricing of Underwritten Offering
GL
Autolus Announces Pricing of Underwritten Offering
AQ
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs  
GL
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs 
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. AUTL Stock
  4. News Autolus Therapeutics plc
  5. Press Releases